Progressive Suppression of Selenium Binding Protein 1 in Gastric Adenoma and Adenocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Human selenium binding protein 1 (SELENBP1) is a protein that binds selenium as a cofactor. The decreased expression of SELENBP1 in several types of carcinomas and its association with a poor prognosis have previously been reported on. In this study, we evaluated the expression of SELENBP1 in low-grade and high-grade epithelial dysplasia/ adenomas and adenocarcinomas. Methods : We analyzed 45 cases of low-grade epithelial dysplasia/adenomas, 42 cases of high-grade epithelial dysplasia/adenomas and 64 cases of adenocarcinomas and all of them were obtained from endoscopic mucosal resection or endoscopic submucosal dissection. We analyzed all of them for their SELENBP1 expression by immunohistochemistry. Eight triple-paired cases of gastric mucosa, adenoma and adenocarcinoma from the same patient were selected for RT-PCR analysis. Results : There was a progressive decrease in the expression of SELENBP1 from the low-grade dysplasia/adenomas (42/45, 93%) to the high-grade dysplasia/adenomas (29/42, 69%) and finally to the adenocarcinomas (24/64, 37%), (p<0.001). The progressive decrease in the SELENBP1 expression was also evident in the eight paired cases that were analyzed by RT-PCR. Conclusions : Our findings demonstrate that the SELENBP1 expression is suppressed in gastric epithelial dysplasia/adenomas and adenocarcinomas. The suppression of SELENBP1 was significantly more frequent and severer in the adenocarcinomas than that in the low-grade dysplasia/ adenomas, and this implies that the suppression of SELENBP1 is a late event in gastric carcinogenesis.
Abstract
Background : Human selenium binding protein 1 (SELENBP1) is a protein that binds selenium as a cofactor. The decreased expression of SELENBP1 in several types of carcinomas and its association with a poor prognosis have previously been reported on. In this study, we evaluated the expression of SELENBP1 in low-grade and high-grade epithelial dysplasia/ adenomas and adenocarcinomas. Methods : We analyzed 45 cases of low-grade epithelial dysplasia/adenomas, 42 cases of high-grade epithelial dysplasia/adenomas and 64 cases of adenocarcinomas and all of them were obtained from endoscopic mucosal resection or endoscopic submucosal dissection. We analyzed all of them for their SELENBP1 expression by immunohistochemistry. Eight triple-paired cases of gastric mucosa, adenoma and adenocarcinoma from the same patient were selected for RT-PCR analysis. Results : There was a progressive decrease in the expression of SELENBP1 from the low-grade dysplasia/adenomas (42/45, 93%) to the high-grade dysplasia/adenomas (29/42, 69%) and finally to the adenocarcinomas (24/64, 37%), (p<0.001). The progressive decrease in the SELENBP1 expression was also evident in the eight paired cases that were analyzed by RT-PCR. Conclusions : Our findings demonstrate that the SELENBP1 expression is suppressed in gastric epithelial dysplasia/adenomas and adenocarcinomas. The suppression of SELENBP1 was significantly more frequent and severer in the adenocarcinomas than that in the low-grade dysplasia/ adenomas, and this implies that the suppression of SELENBP1 is a late event in gastric carcinogenesis.
참고문헌 (23)
- Chang PW, "Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein", J Cell Biochem, 64, pp.217~224 (1997)
- Bansal MP, "DNA sequencing of a mouse liver protein that binds selenium: implications for selenium’s mechanism of action in cancer prevention", Carcinogenesis, 11, pp.2071~2073 (1990)
- Pumford NR, "A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein", Biochem Biophys Res Commun, 182, pp.1348~1355 (1992)
- Giometti CS, "Mouse liver selenium-binding protein decreased in abundance by peroxisome proliferators", Electrophoresis, 21, pp.2162~2169 (2000)
- Porat A, "A 56-kDa selenium-binding protein participates in intra-Golgi protein transport", J Biol Chem, 275, pp.14457~14465 (2000)
- Park JY, "Proteomic analysis of diet-induced hypercholesterolemic mice", Proteomics, 4, pp.514~523 (2004)
- Kim H, "Suppression of human seleniumbinding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival", Proteomics, 6, pp.3466~3476 (2006)
- Yang M, "Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells", Cancer Res, 58, pp.3150~3153 (1998)
- Chen G, "Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas", J Pathol, 202, pp.321~329 (2004)
- Li T, "Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer", Mol Nutr Food Res, 52, pp.1289~1299 (2008)
- He QY, "Diverse proteomic alterations in gastric adenocarcinoma", Proteomics, 4, pp.3276~3287 (2004)
- Huang KC, "Selenium binding protein 1 in ovarian cancer", Int J Cancer, 118, pp.2433~2440 (2006)
- Brown LM, "Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue", Mol Carcinog, 45, pp.613~626 (2006)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Lee HJ, "Gastric cancer in Korea", Gastric Cancer, 5, pp.177~182 (2002)
- Correa P., "Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
- Tahara E., "Genetic pathways of two types of gastric cancer", IARC Sci Publ, pp.327~349 (2004)
- Papp LV, "From selenium to selenoproteins: synthesis, identity, and their role in human health", Antioxid Redox Signal, 9, pp.775~806 (2007)
- Combs GF Jr, "Reduction of cancer mortality and incidence by selenium supplementation", Med Klin (Munich), 92, pp.42~45 (1997)
- Clark LC, "Decreased incidence of prostate cancer with selenium supplementation: results of a doubleblind cancer prevention trial", Br J Urol, 81, pp.730~734 (1998)
- Reid ME, "The nutritional prevention of cancer: 400 mcg per day selenium treatment", Nutr Cancer, 60, pp.155~163 (2008)
- Duffield-Lillico AJ, "Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial", Cancer Epidemiol Biomarkers Prev, 11, pp.630~639 (2002)
- Whanger PD., "Selenium and its relationship to cancer: an update", Br J Nutr, 91, pp.11~28 (2004)